US20170182003A1 - Combination therapies for the treatment of cancer - Google Patents

Combination therapies for the treatment of cancer Download PDF

Info

Publication number
US20170182003A1
US20170182003A1 US15/312,980 US201515312980A US2017182003A1 US 20170182003 A1 US20170182003 A1 US 20170182003A1 US 201515312980 A US201515312980 A US 201515312980A US 2017182003 A1 US2017182003 A1 US 2017182003A1
Authority
US
United States
Prior art keywords
cancers
cancer
methyl
radiation
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/312,980
Other languages
English (en)
Inventor
Xingfeng BAO
Diana ALBU
Mary WOODALL-JAPPE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Priority to US15/312,980 priority Critical patent/US20170182003A1/en
Assigned to EISAI R&D MANAGEMENT CO., LTD. reassignment EISAI R&D MANAGEMENT CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALBU, Diana, BAO, XINGFENG, WOODALL-JAPPE, Mary
Publication of US20170182003A1 publication Critical patent/US20170182003A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • PGE2 prostaglandin E2
  • EP4 prostaglandin E receptor 4
  • the anti-tumor activities of various combinations of an EP4 antagonist with: radiation; antibodies to cytotoxic t-lymphocyte antigen 4 (anti-CTLA4); antibodies to programmed death ligand 1 (anti-PDL1); antibodies to programmed cell death protein 1 (anti-PD1); and anti-metabolites have been examined.
  • the results from this examination have indicated improved and/or synergistic anti-tumor activities by the combination of the EP4 antagonist with the other therapies as compared to single agent treatment alone, and in some embodiments this may result in a memory immune response against the tumor, even as against a different cancer.
  • a method of treating cancer in a subject in need thereof comprising administering an EP4 antagonist in combination with a therapy selected from the group consisting of radiation therapy, antibody therapy and anti-metabolite chemotherapy.
  • the antibody therapy is selected from the group consisting of CTLA4 antibody therapy, PDL1 antibody therapy, and PD1 antibody therapy.
  • the cancer is metastatic cancer.
  • a method of generating a memory immune response in a subject in need thereof comprising administering an amount of an EP4 antagonist in combination with a therapy selected from the group consisting of radiation therapy, antibody therapy and anti-metabolite chemotherapy.
  • the antibody therapy is selected from the group consisting of CTLA4 antibody therapy, PDL1 antibody therapy and PD1 antibody therapy.
  • the cancer treated is selected from the group consisting of breast cancers, cervical cancers, colorectal cancers, endometrial cancers, glioblastomas, head and neck cancers, kidney cancers, liver cancers, lung cancers, medulloblastomas, ovarian cancers, pancreatic cancers, prostate cancers, skin cancers and urinary tract cancers.
  • an EP4 antagonist and a therapy selected from the group consisting of radiation therapy, antibody therapy and/or anti-metabolite chemotherapy for treating cancer and/or generating a memory immune response as disclosed herein.
  • an EP4 antagonist in the preparation of a medicament for a combination therapy with a therapy selected from the group consisting of radiation therapy, antibody therapy and/or anti-metabolite chemotherapy for treating cancer and/or generating a memory immune response as disclosed herein.
  • FIG. 1A to FIG. 1B Significantly improved anti-tumor growth activity of radiation/ER-886046 combination therapy compared with radiation alone.
  • Panel shown in FIG. 1A Average tumor sizes of the CT26 tumor-bearing mice that received 9 Gy radiation+ER-886046, 9 Gy radiation alone, or vehicle alone.
  • Panel shown in FIG. 1B Average animal body weight of the CT-26 tumor-bearing mice.
  • Radiation treatment 9 Gy single dose on day 9; ER-886046 dosing: 150 mg/kg, oral (po) administration daily from day 9 to day 32.
  • Administration of radiation and ER-886046 to the tumor-bearing mice is indicated by the arrows and bars, respectively.
  • N 10-12 per group. *, p ⁇ 0.05, student t-test.
  • FIG. 4A to FIG. 4C Long lasting anti-tumor effect with a memory immune response by ER-886046/radiation treatment.
  • Panel shown in FIG. 4A Tumor growth in the cured mice by ER-886046 and radiation combination treatment or in the na ⁇ ve BalB/c mice that received injection of CT26 cells.
  • Panel shown in FIG. 4B Tumor growth of secondarily challenged CT-26 tumors in the cured mice or in na ⁇ ve mice.
  • FIG. 5A to FIG. 5B Anti-tumor effect of ER-886046/radiation in a bilateral tumor model.
  • Two similar-sized CT-26 tumors were grown in a host by injecting CT26 cells subcutaneously on both right and left flanks of BalB/c mice. Radiation was applied to the right flank tumor on both day 9 and day 13 as indicated by arrows in panel A.
  • ER-886046 was administered daily po to the animals at a dose of 150 mg/kg as indicated by the bars.
  • ER-886046 was dosed to animals from day 9 to day 27.
  • Panel shown in FIG. 5A Average size of the right flank tumor that received radiation and ER-886046. Panel shown in FIG.
  • FIG. 6A to FIG. 6B Anti-pulmonary metastasis activity of ER-886046/radiation in breast 4T1 tumor model.
  • 4T1-luc2 cells were subcutaneously (sc) inoculated into the BalB/c mice. When the average size of tumors reached 100 mm 3 , the tumors were radiated with a dose of 9 Gy once with or without daily oral administration of ER-886046 at dose of 150 mg/kg.
  • Panel shown in FIG. 6A At the end of study on day 27, lung metastasis of the animals was analyzed and quantified by luciferase expression.
  • Panel shown in FIG. 6B Representative IVIS images of each group are shown. Student t-test was used for statistic analysis.
  • FIG. 7A to FIG. 7B Radiation and ER-886046 worked synergistically to modify the intratumoral immunity.
  • Panel shown in FIG. 7A Quantification of myeloid cells (CD11b + ) and cytotoxic T cells (CD8 + ) in the CT26 tumors that received 9 Gy alone, 9 Gy+ER-886046, or vehicle alone.
  • Panel shown in FIG. 7B Quantification of myeloid-derived suppressor cells (MDSC cells, CD11b + Gr1 + ) in the tumors. Radiation was given once to the tumors on the day of randomization, while ER-886046 was administered po daily administrated at 150 mg/kg to the animals for 7 consecutive days after randomization. The tumors were analyzed by flow cytometry one day after the last dose of ER-886046. **, p ⁇ 0.01; ns, not significant; student t-test.
  • FIG. 8A to FIG. 8B Synergistic anti-tumor activity of ER-886046 with anti-CTLA4 in B16F10 tumors.
  • Panel shown in FIG. 8A Anti-tumor growth activities of anti-CTLA4 and ER-886046 in B16F10 melanoma tumors growing in C57BL/6 mice.
  • Panel shown in FIG. 8B Animal body weight changes of the treatment groups.
  • Anti-CTLA4 dosing 200 ⁇ g for the first intravenous (iv) injection on day 3 after transplantation and 100 ⁇ g for the other three iv injections on days 6, 9 and 12 as indicated by the arrows.
  • ER-886046 dosing 150 mg/kg, po daily administration from day 3 to day 15 as indicated by the bars. *, p ⁇ 0.05; **, p ⁇ 0.01; ns, not significant; student t test.
  • FIG. 9A to FIG. 9B Enhanced anti-tumor activities of anti-PDL1 or anti-PD1 by ER-886046 in CT26 tumors.
  • Panel shown in FIG. 9A Activities of anti-PDL1 plus ER-886046 and anti-PDL1 alone.
  • Anti-PDL1 dosing 200 ⁇ g per iv injection on days 9, 12, 15 and 18 post cell implantation as indicated by the arrows;
  • ER-886046 dosing 150 mg/kg, po daily administration from day 9 to day 19 post cell implantation as indicated by the bar.
  • Panel shown in FIG. 9B Activities of anti-PD1 plus ER-886046 and anti-PD1 alone.
  • Anti-PD1 dosing 200 ⁇ g per iv injection on days 9, 12, 15, 18 and 21 post cell implantation as indicated by the arrows; ER-886046 dosing: 150 mg/kg, po daily administration from day 9 to day 23 post cell implantation as indicated by the bar. *, p ⁇ 0.05; ***, p ⁇ 0.001; student t-test.
  • FIG. 10 Enhanced anti-tumor activity by combination therapy of ER-886046 and anti-metabolite chemotherapy with radiation compared to anti-metabolite chemotherapy with radiation alone.
  • Gemcitabine and RT dosing a single 40 mg/kg dose of gemcitabine and a single 6 Gy dose of RT, was administered on day 27 post tumor cell injection.
  • ER-8806046 was administered daily in an amount of 150 mg/kg from day 27 post tumor cell injection until the end of the study.
  • FIG. 11A to FIG. 11B Additional experiments with combination therapy of ER-886046 and anti-metabolite chemotherapy with radiation compared to anti-metabolite chemotherapy with radiation alone.
  • Panel shown in FIG. 11A Gemcitabine and RT dosing: a single 40 mg/kg dose of gemcitabine and a single 6 Gy dose of RT, was administered on day 19 post tumor cell injection.
  • ER-8806046 was administered daily in an amount of 150 mg/kg from day 19 post tumor cell injection until the end of the study.
  • Panel shown in FIG. 11B Gemcitabine and RT dosing: a single 40 mg/kg dose of gemcitabine and a single 6 Gy dose of RT, was administered on day 12 post tumor cell injection.
  • EP4 antagonist refers to a compound which inhibits or blocks the cellular signaling triggered by the interaction of PGE2 with the EP4 receptor.
  • EP4 antagonists include, but are not limited to, ER-819762, MK-2894, MF 498, ONO-AE3-208, evatanepag, ONO-AE2-227, CJ-042794, EP4A, BGC201531, CJ-023423, ONO-AE3-240, GW 627368 and AH23848, such as are listed in the IUPHAR database as antagonists of the EP4 receptor.
  • ER-885290 ER-885740, ER-885741, ER-886045, ER-886046 (E7046), ER-886074, ER-885290, ER-885740 and ER-885741, which are described in WO 2012/039972.
  • CTLA4 antibody or “anti-CTLA4” refers to an antibody or antibodies directed towards cytotoxic t-lymphocyte antigen 4 (CTLA4).
  • exemplary antibodies include, but are not limited to, antibodies that are CTLA4 antagonists or the CTLA4 antibodies as set forth in U.S. Pat. Nos. 8,685,394 and 8,709,417.
  • Some embodiments of the antibody include MDX-010 (ipilimumab, Bristol-Myers Squibb) and CP-675,206 (tremelimumab, Pfizer). In a particular embodiment, the antibody is ipilimumab.
  • PDL1 antibody or “anti-PDL1” refers to an antibody directed towards programmed death ligand 1 (PDL1).
  • exemplary antibodies include, but are not limited to, the antibodies set forth in U.S. Pat. Nos. 8,217,149, 8,383,796, 8,552,154 and 8,617,546.
  • the antibody is MPDL3280A (Roche).
  • PD1 antibody or “anti-PD1” refers to an antibody directed towards programmed death protein 1 (PD1).
  • exemplary antibodies include, but are not limited to, the antibodies set forth in U.S. Pat. Nos. 7,029,674, 7,488,802, 7,521,051, 8,008,449, 8,354,509, 8,617,546 and 8,709,417.
  • Particular embodiments of the antibody include MDX-1106 (nivolumab, Bristol-Myers Squibb), labrolizumab (Merck), and pembrolizumab (KEYTRUDA®, Merck).
  • Treatment refers to alleviating, inhibiting and/or reversing the progress of a cancer in a subject in need thereof.
  • the term “treating” is inclusive of any indicia of success in the treatment or amelioration of the cancer, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the subject; delaying or slowing in the rate of progression, etc.
  • Measurement of the treatment or amelioration may be based on, e.g., the results of a physical examination, a pathological test and/or a diagnostic test as known in the art.
  • Treating may also refer to reducing the incidence or onset of a cancer, or a recurrence thereof (such as a lengthening in time of remission), as compared to that which would occur in the absence of the measure taken.
  • Effective amount refers to an amount that is effective for treating a cancer as noted through clinical testing and evaluation, patient observation, and/or the like.
  • An “effective amount” can further designate an amount that causes a detectable change in biological or chemical activity. The detectable changes may be detected and/or further quantified by one skilled in the art for the relevant mechanism or process.
  • an “effective amount” can designate an amount that maintains a desired physiological state, i.e., reduces or prevents significant decline and/or promotes improvement in the condition.
  • An “effective amount” can further refer to a therapeutically effective amount.
  • Subject refers a mammalian subject, and particularly a human subject, including a male or female subject, and including a neonatal, infant, juvenile, adolescent, adult or geriatric subject, and further is inclusive of various races and ethnicities.
  • a pharmaceutically acceptable salt refers to a relatively non-toxic, inorganic or organic acid salt of a compound of the invention. These salts may be prepared in situ during the final isolation and purification of the compounds or by reacting the purified compound in its free form separately with a suitable organic or inorganic acid and isolating the salt thus formed.
  • Representative acid salts include, but are not limited to, acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tanna
  • cancers may include cancers that are the result of genetically inherited mutations.
  • examples of such cancers include, but are not limited to, breast cancers, cancers which can be related to Li-Fraumeni syndrome, for example, childhood sarcomas, leukemias and brain cancers, cancers which can be related to Lynch syndrome, for example, colon cancers, bile duct cancers, brain cancers, endometrial cancers, kidney cancers, ovarian cancers, pancreatic cancers, small intestinal cancers, stomach cancers and ureter cancers, lung cancers, melanomas, prostate cancers, retinoblastomas, thyroid cancers and uterine cancers.
  • cancer can be the result of acquired mutations, for example, mutations resulting from diet, environment and/or lifestyle, or somatic mutations.
  • cancers may include, but are not limited to, adrenal cancer, adrenal cortex cancer, bladder cancer, brain cancer, primary brain cancer, glioma, glioblastoma, breast cancer, cervical cancer, colon cancer (non-limiting examples include colorectal carcinomas such as colon adenocarcinoma and colon adoma), endometrial cancer, epidermal cancer, esophageal cancer, gall bladder cancer, genitourinary cancer, head or neck cancer, kidney cancer, liver cancer, lung cancer (non-limiting examples include adenocarcinoma, small cell lung cancer and non-small cell lung cancer), lymphomas (non-limiting examples include B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma), melanoma, malignant melanoma,
  • Metal cancer refers to a cancer in which cancerous cells from an organ or body part has spread (through “metastasis”) to another, non-adjacent organ or body part.
  • the cancer at the non-adjacent organ or body part (“secondary tumor” or “metastatic tumor”) includes cancerous cells originating from the organ or body part from which the cancer or cancerous cells has spread.
  • Sites in which the secondary tumor may occur include, but are not limited to, lymph nodes, the lungs, liver, brain and/or bones.
  • the EP4 antagonist used in the methods and compositions taught herein is a compound of Formula (I):
  • Fluoromethyl refers to a methyl group substituted with one or more fluoro atoms (e.g., monofluoromethyl, difluoromethyl, trifluoromethyl).
  • Fluoromethoxy refers to an fluoromethyl group, as previously defined, attached to the principal carbon chain through an oxygen atom.
  • one of R 1a and R 1b is hydrogen, and the other is methyl;
  • R 2 is methyl, difluoromethyl, or trifluoromethyl;
  • R 3 is methyl;
  • R 4 is chloro, fluoro, trifluoromethyl, difluoromethyl, methyl, methoxy, difluoromethoxy, or trifluoromethoxy;
  • R 5 is hydrogen, chloro, fluoro, methyl, or methoxy; and R 6 and R 7 are hydrogen.
  • R 5 is hydrogen.
  • R 4 is selected from chloro, trifluoromethyl, difluoromethyl, difluoromethoxy, and trifluoromethoxy.
  • R 1a and R 1b are taken together to form a cyclopropyl ring;
  • R 2 is methyl, trifluoromethyl, or difluoromethyl;
  • R 3 is methyl;
  • R 4 is trifluoromethyl, difluoromethyl, chloro, or fluoro; and
  • R 6 and R 7 are hydrogen.
  • the compound of Formula (I) is:
  • the compound of Formula (I) is:
  • an EP4 antagonist is administered in combination with an additional therapy or agent useful for inhibiting tumor growth and/or treating cancer, i.e., a combination therapy.
  • the administration of two or more agents/therapies means that the therapies are administered closely enough in time that the administration of or presence of one alters the biological effects of the other.
  • the therapies may be administered simultaneously (concurrently) or sequentially.
  • Simultaneous administration may be carried out, e.g., by mixing two or more agents prior to administration, or by administering the agent/therapy at the same point in time but at different anatomic sites or using different routes of administration, or administered at times sufficiently close that the results observed are indistinguishable from those achieved when the agents/therapies are administered at the same point in time.
  • simultaneous administration of one or more agents with radiation may be carried out by administering the agent(s) at the same point in time as the radiation is applied, or at times sufficiently close that the results observed are indistinguishable from those achieved when the agent(s) and radiation are administered at the same point in time.
  • Sequential administration may be carried out by administering the agents/therapies at different points in time, e.g., administering an agent/therapy at some point in time prior to or after administration of one or more other agents/therapies, such that the administration of the agents/therapies in combination enhances the therapeutic effect of cancer treatment.
  • an EP4 antagonist is administered at some point in time prior to the initial administration of radiation therapy, antibody therapy and/or anti-metabolite chemotherapy.
  • the radiation therapy, antibody therapy and/or anti-metabolite chemotherapy may be administered at some point in time prior to the administration of the EP4 antagonist, and optionally, administered again at some point in time after the administration of the EP4 antagonist.
  • administration of the EP4 antagonist in combination with radiation therapy, antibody therapy and/or anti-metabolite chemotherapy results in an enhancement of said radiation therapy, antibody therapy and/or anti-metabolite chemotherapy such that, for example, a smaller dosage of the radiation, antibody therapy and/or anti-metabolite chemotherapy may be effective for treatment.
  • the treatment of cancer may comprise an abscopal effect and/or provide a memory immune response.
  • An “abscopal” effect is a phenomenon in the treatment of a metastatic cancer in which localized treatment of a particular tumor or cancer with, for example, radiation therapy, results in the shrinking and disappearance of non-localized disease, tumors or cancer, such as those resulting from metastasis that are distant from the site of localized treatment, thus leading to the disappearance of disease, tumors or cancer throughout the subject or patient.
  • An abscopic effect differs from effects that may occur on tissues adjacent to the localized treatment, such as, for example, bystander effects that may result from radiation therapy.
  • a “memory immune response” results when the provided treatment for cancer facilitates the adaptation of the immune system and the immune response of the subject or patient in its ability to slow, reduce or prevent the return or the recurrence, e.g., lengthening the time of remission, of the disease, tumor or cancer being treated in the subject or patient.
  • the memory immune response may slow, reduce or prevent the development of tumors or cancers that are different than the cancer being treated, e.g., through epitope spreading.
  • the EP4 antagonist, antibody and/or anti-metabolite as used herein may be formulated for administration in a pharmaceutical carrier in accordance with known techniques. See, for example, Remington, The Science and Practice of Pharmacy (9th Ed. 1995).
  • the active compound (including the physiologically acceptable salts thereof) is typically admixed with, inter alia, an acceptable carrier.
  • the carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the patient.
  • the carrier may be a solid or a liquid, or both, and is preferably formulated with the compound as a unit-dose formulation, for example, a tablet, which may contain from 0.01 or 0.5% to 95% or 99% by weight of the active compound.
  • One or more active compounds may be incorporated in the formulations of the invention, which may be prepared by any of the well known techniques of pharmacy comprising admixing the components, optionally including one or more accessory ingredients and/or excipients.
  • any of the composition(s), carrier(s), accessory ingredient(s) excipient(s) and/or the formulation(s) of the invention comprise ingredients that are from either natural or non-natural sources.
  • any component of the composition(s), carrier(s), accessory ingredient(s), excipient(s) and/or the formulation(s) of the invention may be provided in a sterile form.
  • a sterile carrier include endotoxin-free water or pyrogen-free water.
  • the EP4 antagonist, antibody and/or anti-metabolite can be administered to subjects by any suitable route, including orally (inclusive of administration via the oral cavity and further including administration via an orogastric feeding tube), intraperitoneally, parenterally, by inhalation spray, topically (i.e., both skin and mucosal surfaces, including airway surfaces), transdermally, rectally, nasally (including a nasogastric feeding tube), sublingually, buccally, vaginally or via an implanted reservoir.
  • suitable route including orally (inclusive of administration via the oral cavity and further including administration via an orogastric feeding tube), intraperitoneally, parenterally, by inhalation spray, topically (i.e., both skin and mucosal surfaces, including airway surfaces), transdermally, rectally, nasally (including a nasogastric feeding tube), sublingually, buccally, vaginally or via an implanted reservoir.
  • parenteral includes subcutaneous, intramuscular, intradermal, intravenous, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the EP4 antagonist, antibody and/or anti-metabolite is administered orally.
  • the EP4 antagonist, antibody and/or anti-metabolite is administered intravenously.
  • the amount of the EP4 antagonist, antibody and/or anti-metabolite that may be combined with the excipient materials to produce a composition in a single dosage form will vary depending upon the host treated, and the particular route of administration.
  • the EP4 antagonist, antibody and/or anti-metabolite is provided as part of a sterile composition/formulation comprising the EP4 antagonist, antibody and/or anti-metabolite and an acceptable carrier and/or excipient.
  • the EP4 antagonist is administered to the subject in an effective amount.
  • An effective amount is generally 0.01 mg/kg to 500 mg/kg body weight per day.
  • the pharmaceutically acceptable compositions may be formulated so that a dosage of from 0.01 mg/kg to 200 mg/kg or from 0.01 mg/kg to 100 mg/kg body weight per day of the compound can be administered to a patient receiving these compositions (e.g., based on a 75 kg human, a dosage of from 0.75 mg to 7.5 g or 15 g).
  • the compositions of the present invention are formulated to provide a dosage of from 0.01 mg/kg to 70 mg/kg (e.g., based on a 75 kg human, a dosage of from 0.75 mg to 5.25 g).
  • the effective dose of the EP4 antagonist is from about 0.5 to about 250 mg/kg, 1 to about 250 mg/kg, from about 2 to about 200 mg/kg, from about 3 to about 120 mg/kg, from about 5 to about 250 mg/kg, from about 10 to about 200 mg/kg, or from about 20 to about 120 mg/kg.
  • effective dosages include about 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 8 mg/kg, 10 mg/kg, 20 mg/kg, 25 mg/kg, 40 mg/kg, 50 mg/kg, 60 mg/kg, 75 mg/kg, 100 mg/kg, 120 mg/kg, 150 mg/kg, 175 mg/kg, 200 mg/kg, 225 mg/kg, 250 mg/kg, and 300 mg/kg.
  • Dosage forms can be in the form, e.g., of tablets or capsules, and the effective dose may be provided in one or more tablets, capsules or the like, and be provided once a day or throughout the day at intervals, e.g., of 4, 8 or 12 hours.
  • Tablets or capsules could contain, e.g., 10, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000, 1,100, or 1,250 mg of compound.
  • administration to a human subject of the EP4 antagonist in some embodiments may comprise a daily dosage of the EP4 antagonist in the range of 100-1,250, 150-1,000, 200-800, or 250-750 mg, which daily dosage can be administered either once a day in its entirety or fractions of which are administered throughout the day in intervals.
  • Liquid formulations can also be prepared so that any dosage may readily and conveniently be dispensed.
  • the antibody e.g., anti-CTLA4, anti-PDL1 or anti-PD1 will generally be mixed, prior to administration, with a non-toxic, pharmaceutically acceptable carrier substance (e.g., normal saline or phosphate-buffered saline), and may be administered using any medically appropriate procedure, for example, including but not limited to, intravenous or intra-arterial administration, and injection into the cerebrospinal fluid.
  • a non-toxic, pharmaceutically acceptable carrier substance e.g., normal saline or phosphate-buffered saline
  • intraperitoneal intradermal, intracavity, intrathecal or direct administration to a tumor or to an artery supplying the tumor may be advantageous.
  • the effective dose of the antibody is from about 5 to about 250 mg/kg, from about 10 to about 200 mg/kg, or from about 20 to about 120 mg/kg.
  • effective dosages include 5 mg/kg, 10 mg/kg, 20 mg/kg, 25 mg/kg, 40 mg/kg, 50 mg/kg, 60 mg/kg, 75 mg/kg, 100 mg/kg, 120 mg/kg, 150 mg/kg, 175 mg/kg, 200 mg/kg, 225 mg/kg, 250 mg/kg, and 300 mg/kg.
  • Dosage forms can be in the form, e.g., of tablets or capsules, and the effective dose may be provided in one or more tablets, capsules or the like, and be provided once a day or throughout the day at intervals, e.g., of 4, 8 or 12 hours.
  • Tablets or capsules for example, could contain, e.g., 10, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, or 1,000 mg of antibody.
  • Liquid formulations can also be prepared so that any dosage may readily and conveniently be dispensed.
  • the antibody is administered to the subject in an effective amount.
  • An effective amount is generally 0.01 mg/kg to 500 mg/kg body weight per day.
  • the pharmaceutically acceptable compositions may be formulated so that a dosage of from 0.01 mg/kg to 200 mg/kg or from 0.01 mg/kg to 100 mg/kg body weight per day of the compound can be administered to a patient receiving these compositions (e.g., based on a 75 kg human, a dosage of from 0.75 mg to 7.5 g or 15 g).
  • the compositions of the present invention are formulated to provide a dosage of from 0.01 mg/kg to 70 mg/kg (e.g., based on a 75 kg human, a dosage of from 0.75 mg to 5.25 g).
  • An effective amount of the antibody may be, for example, 0.05 mg/kg, 0.1 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg or 8 mg/kg per dose (e.g., based on a 75 kg human, a dosage of from 3.75 mg to 600 mg).
  • the dosage of the antibody may be administered once, twice, three times, four times, five times or more per week, once every week, once every two weeks, or even once every three weeks during the course of treatment.
  • the timing of the dosing may be daily, once every two days, once every three days, once every four days, once every five days, weekly, once every two weeks or once every three weeks.
  • Formulations comprising the antibody may be prepared so that any dosage may readily and conveniently be dispensed.
  • Random therapy refers to the medical use of ionizing radiation, particularly for the treatment of cancer.
  • the medical use of ionizing radiation in the treatment of cancer results in the reduction of and/or killing of cancer cells in the subject.
  • Radiation therapy may be administered by any manner that would be understood by one of skill in the art.
  • Examples of radiation utilized in radiation therapy include, but are not limited to, photon, ionizing or charged particle radiation, such as X-rays or protons.
  • Examples of radiation therapy include, but are not limited to: external beam radiation therapy or teletherapy; brachytherapy or sealed beam source therapy; and systemic radioisotope therapy or unsealed source radiotherapy.
  • the dosage of radiation administered may vary depending upon the target cancer or tumor.
  • dosages of radiation may be 80 grays (Gy), 60 Gy, 40 Gy, 20 Gy, 12 Gy, 10 Gy, 9 Gy, 8 Gy, 7 Gy, 6 Gy, 5 Gy, 4 Gy, 3 Gy, 2 Gy or 1 Gy, including any amount in between those indicated, and/or ranges thereof.
  • the dosage is 12 Gy, 9 Gy, 6 Gy or 3 Gy.
  • the dosage of radiation may be administered once, twice, three times, four times, five times or more per week, for one, two, three, four or five weeks or more during the course of treatment.
  • the anti-metabolite is administered to the subject in an effective amount.
  • An effective amount is generally 0.01 mg/kg to 500 mg/kg body weight per day.
  • the pharmaceutically acceptable compositions may be formulated so that a dosage of from 0.01 mg/kg to 200 mg/kg or from 0.01 mg/kg to 100 mg/kg body weight can be administered to a patient receiving these compositions (e.g., based on a 75 kg human, a dosage of from 0.75 mg to 7.5 g or 15 g).
  • the compositions of the present invention are formulated to provide a dosage of from 0.01 mg/kg to 70 mg/kg (e.g., based on a 75 kg human, a dosage of from 0.75 mg to 5.25 g).
  • the effective dose of the anti-metabolite is from about 0.5 to about 250 mg/kg, 1 to about 200 mg/kg, from about 2 to about 175 mg/kg, from about 3 to about 150 mg/kg, from about 5 to about 125 mg/kg, from about 10 to about 100 mg/kg, or from about 20 to about 80 mg/kg.
  • effective dosages include about 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 8 mg/kg, 10 mg/kg, 20 mg/kg, 25 mg/kg, 40 mg/kg, 50 mg/kg, 60 mg/kg, 75 mg/kg, 100 mg/kg, 120 mg/kg, 150 mg/kg, 175 mg/kg, 200 mg/kg, 225 mg/kg, 250 mg/kg, and 300 mg/kg.
  • Dosages may be provided, e.g., in a liquid form suitable for parenteral administration (e.g., intravenous), or a form suitable for oral administration, e.g., tablets or capsules, and the effective dose may be provided in one or more tablets, capsules or the like.
  • the anti-metabolite is administered simultaneously with radiation.
  • antibody and “antibodies” as used herein is inclusive of all types of immunoglobulins, including IgG, IgM, IgA, IgD, and IgE, or fragments thereof, that may be appropriate for the medical uses disclosed herein.
  • the antibodies may be monoclonal or polyclonal and may be of any species of origin, including, for example, mouse, rat, rabbit, horse, or human.
  • Antibody fragments that retain specific binding to the protein or epitope, for example, CTLA4, PDL1 or PD1, bound by the antibody used in the present invention are included within the scope of the term “antibody.” Such fragments can be produced by known techniques.
  • the antibodies may be chimeric or humanized, particularly when they are used for therapeutic purposes. The antibody may be obtained or prepared using methods known in the art.
  • Antibody therapy refers to the medical use of antibodies that bind a target cell or protein to treat cancer and/or stimulate an immune response in a subject that results in the recognition, attack and/or destruction of cancerous cells in the subject, and in some embodiments of the invention, to activate or stimulate a memory immune response in a subject that results in the subsequent recognition, attack and/or destruction of cancerous cells in the subject.
  • CTLA4 antibody therapy refers to the use of antibodies directed toward cytotoxic t-lymphocyte antigen 4 (anti-CTLA4) in modulating an immune response in a subject.
  • the CTLA4 antibody inhibits or blocks the action of CTLA4 signaling that results in the inhibition of T-cell activation in the attack and destruction of cancer cells.
  • Suitable antibodies for this use include, but are not limited to, antibodies that are CTLA4 antagonists or the CTLA4 antibodies as set forth in U.S. Pat. Nos. 8,685,394 and 8,709,417.
  • Some embodiments of the antibody include MDX-010 (ipilimumab, Bristol-Myers Squibb) and CP-675,206 (tremelimumab, Pfizer). In a particular embodiment, the antibody is ipilimumab.
  • PDL1 antibody therapy refers to the use of antibodies directed toward programmed death ligand 1 (anti-PDL1) in modulating an immune response in a subject.
  • the PDL1 antibody inhibits or blocks the interaction of PDL1 with programmed cell death protein 1 (PD1), wherein the blockage of the interaction between PDL1 and PD1 inhibits the negative regulation of T-cell activation by PD1 to attack and destroy cancer cells.
  • Suitable antibodies for this use include, but are not limited to, the antibodies set forth in U.S. Pat. Nos. 8,217,149, 8,383,796, 8,552,154 and 8,617,546.
  • the antibody is MPDL3280A (Roche).
  • PD1 antibody therapy refers to the use of antibodies directed toward programmed cell death protein 1 PD1 (anti-PD1) in modulating an immune response in a subject.
  • the PD1 antibody inhibits or blocks the interaction of PD1 with PDL1, wherein the inhibition or blockage of the interaction between PDL1 and PD1 inhibits the negative regulation of T-cell activation by PD1 to attack and destroy cancer cells.
  • Suitable antibodies for this use include, but are not limited to, the antibodies set forth in U.S. Pat. Nos. 7,029,674, 7,488,802, 7,521,051, 8,008,449, 8,354,509, 8,617,546 and 8,709,417.
  • Particular embodiments of the antibody include MDX-1106 (nivolumab, Bristol-Myers Squibb), labrolizumab (Merck), and pembrolizumab (KEYTRUDA®, Merck).
  • Anti-metabolite chemotherapy refers to the use of an anti-metabolite chemotherapeutic in the treatment of a subject.
  • Anti-metabolite refers to a group of molecules that impede DNA and RNA synthesis. Examples of anti-metabolites include, but are not limited to, anti-folates, fluoropyrimidines, deoxynucleoside analogues and thiopurines. Anti-folates include methotrexate and pemetrexed. Fluoropyrimidines include fluorouracil and capecitabine.
  • Deoxynucleoside analogues include cytarabine, gemcitabine, decitabine, 5-azacytidine (VIDAZA), fludarabine, nelarabine, cladribine, clofarabine and pentostatin.
  • Thiopurines include thioguanine and mercaptopurine.
  • the anti-metabolite is gemcitabine. In another embodiment, the anti-metabolite is capecitebine.
  • ER-886046 was generated by Eisai Inc. (Andover, Mass.).
  • the in vivo ready antibody against CTLA4 (clone 9H10) and its isotype control were obtained from BioXCell (Wester Riverside, N.H.); the antibody against PDL1 (clone 10f.9G2) and its control (clone LTF-2) were obtained from TONBO Bioscience (San Diego, Calif.); and the antibody against mouse PD1 (clone RMP1-14) and its isotype control were obtained from BioXcell (Wester Riverside, N.H.).
  • Methyl cellulose and collagenase I was purchased from Sigma.
  • Fluorescence-labeled antibodies for mouse CD45 (clone 30-F11), CD8 (clone 53-6.7), CD11b (clone M1/70), Gr1 (clone RB6-8C5) were obtained from eBioscience (San Diego, Calif.).
  • a biological irradiator X-RAD 320 from Precision X-Ray was used for animal tumor radiation.
  • Flow cytometric analysis was conducted using a 6-color BD Canto-1 flow cytometic machine (BD Biosciences) equipped with software FlowJo version 7.6.
  • the IVIS spectrum was purchased from Perkin Elmer equipped with software of Living Image version 4.3.1.
  • Mouse colon CT26 cells (CRL-2638), melanoma B16F10 cells (CRL-6475) and breast 4T1 cells (CRL-2539) were purchased from American Tissue Culture Collection. Luciferase-expressing 4T1 cells (4T1-luc2) were obtained from Perkin Elmer. All cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum in a humidified incubator at 37° C. in a 5% carbon dioxide atmosphere and sub-cultured twice weekly until the necessary number of cells for inoculation of mice was obtained.
  • BalB/c and C57BL/6 female mice at 4-6 weeks in age were purchased from Charles River Laboratories. The animals were housed in microisolator cages, up to five per cage with a 12 h light/dark cycle. Cages were changed twice weekly. The animals were observed daily and clinical signs were noted. All experimental procedures were approved by the animal laboratories of Eisai Inc., or of Southern Research Institute, which are each AAALAC accredited.
  • mice were radomized based on the tumor size followed by treatments with radiation at 3 or 9 Gy dose per treatment, anti-PDL1 at 200 ⁇ g/mouse per intraperitoneal injection (ip), or anti-CTLA4 at 200 or 100 m/mouse per ip injection with or without orally administration of ER-886046 at a dose of 150 mg/kg.
  • the tumor sizes were measured twice a week by a digital caliper (Mitutoyo Corp), and the volume was calculated using the formula (l ⁇ w 2 )/2 mm 3 , where l and w refer to the larger and smaller perpendicular dimensions collected at each measurement.
  • Graphs of group tumor sizes (mean ⁇ SEM) and body weights (mean ⁇ SEM) versus time were plotted using software GraphPad Prism 6 (Lake Forest, Calif.). Student t-test and Gehan-Breslow-Wilcoxon test were used for statistical analysis.
  • CT26 cells and 4T1 cells were individually sc injected into the different flanks of the same mouse, and the growth of each tumor was measured and graphed as described above. Na ⁇ ve mice that received neither cancer cell injection nor drug treatment were included as controls.
  • the cells were inoculated and the tumor-bearing mice were radomized on day-10 based on the size of primary tumors.
  • the mice in all treatment groups were intranasally administered luciferin and the lungs were resected and analysed for luciferase expression using IVIS instrument. Quantification of the luciferase activity in the lungs was achieved by software Living Image.
  • CT26 tumors with or without treatments received were surgically resected and minced by physical pressure, followed by digestion with collagenase I at 1 mg/ml at 37° C. for 1 h.
  • the single cell mixtures from the digestion were labelled by incubation with fluorescent antibodies against immune cell antigens and analysed by flow cytometry. Cell population calculation was performed by software FlowJo 7.6.
  • FIG. 1A shows the average tumor sizes of the treatment groups. Radiation alone showed significant tumor growth inhibition in the period of days 9-32, followed by a rapid tumor regrowth compared with control group. In contrast, treatment with ER-886046 and radiation produced sustained tumor growth inhibition until the end of the study on day 49, where no significant tumor growth was noticed in comparison with the tumor size before the treatments. The anti-tumor activity of the combination group was statistically significantly improved as compared to the radiation alone. Addition of ER-886046 to the treatment regime did not impact the gross health and animal body weight as compared to the radiation alone ( FIG. 1B ).
  • Induction of anti-tumor immune response can be systemic and thus highly valuable for treating metastatic cancer, which has multiple lesions in one host.
  • To mimic the large metastatic lesions in mice we simultaneously grew CT26 tumors on both sides of an individual mouse by subcutaneously injecting cancer cells. The tumors on the right side of the mice were treated with both radiation and ER-886046. The tumors on the left side of the mice received ER-886046 only. Measurements of the tumors on the right side of the mice that received both radiation and ER-886046 showed better tumor growth suppression compared with those that received radiation alone or ER-886046 alone ( FIG. 5A ).
  • luciferase-expressing mouse breast 4T1-luc2 tumors were grown subcutaneously in BalB/c mice.
  • the primary tumors were treated with vehicle, ER-886046, single radiation at 9 Gy, and combination of ER-886046 and radiation.
  • Treatment on radiation was given on day-9, and ER-886046 was orally administered daily from days 9-27.
  • the mice in all treatment groups were intranasally administered luciferin and the lungs were resected and analyzed for luciferase expression. Quantification of the luciferase expression showed a significant reduction in the combination treatment only ( FIG. 6A and FIG. 6B ) indicating of a reduced spontaneous lung metastasis.
  • Anti-CTLA4 (Ipilimumab) is now an approved immune therapy for metastatic melanoma, which blocks CTLA4 signaling in immune cells, especially the T cells.
  • ER-886046 influences the anti-tumor activity of anti-CTLA4 in a mouse melanoma B16F10 model.
  • FIG. 8A ER-886046 alone had minimal activity in this model, and anti-CTLA4 alone showed some but non-statistically significant activity.
  • combination of ER-886046 and anti-CTLA4 treatment showed a highly significant anti-tumor activity. No animal body weight loss was observed for the combination therapy treatments. The results indicated a synergistic anti-tumor activity for the combination of ER-886046 and anti-CTLA4 therapy in the preclinical model.
  • Anti-PD1 and anti-PDL1 are currently in clinical trials for potential cancer immune therapeutic use.
  • ER-886046 we tested the combination therapies in CT-26 tumor model.
  • Anti-PDL1 showed some but non-significant anti-tumor growth activity ( FIG. 9A ), while anti-PD1 displayed significant activity by itself ( FIG. 9B ).
  • FIG. 9A shows some but non-significant anti-tumor growth activity
  • FIG. 9B shows significant activity by itself
  • addition of ER-886046 produced better anti-tumor activity compared to anti-PD1 or anti-PDL1 alone indicates a benefit of having the combination of ER-886046 and these antibody-based immune therapies for cancer management.
  • ER-886046 Combination of ER-886046 with radiation, anti-CTLA4, anti-PDL1, or anti-PD1 had significant anti-tumor activity in preclinical animal models. Inclusion of ER-886046 in the combination treatments enhanced the tumor growth suppression and even tumor rejection compared to a single agent or method alone and thus can have therapeutic use in clinic for treating cancer patients.
  • ER-886046 Choen et al. British J Pharmacol , (2010) 160, 292-310
  • a specific prostaglandin E 2 receptor 4 antagonist was generated by Eisai Inc. (Andover, Mass.).
  • Gemcitabine hydrochloride and methyl cellulose were purchased from Sigma (St Louis, Mo.).
  • a biological irradiator X-RAD 320 from Precision X-Ray was used for animal tumor radiation.
  • Mouse colon CT26 cells and pancreatic PAN02 cells were purchased from American Tissue Culture Collection and National Cancer Institute DCTD Repository, respectively. Cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum in a humidified incubator at 37° C. in a 5% carbon dioxide atmosphere and sub-cultured twice weekly until the necessary number of cells for inoculation of mice was obtained.
  • BalB/c and C57BL/6 female mice at 4-6 weeks in age were purchased from Charles River Laboratories. The animals were housed in microisolator cages, up to five per cage with a 12 h light/dark cycle. Cages were changed twice weekly. The animals were observed daily and clinical signs were noted. All experimental procedures were approved by the Institutional Animal Care and Use Committee of Eisai Inc. The animal laboratories are AAALAC accredited.
  • mice In vitro cultured cancer cells were harvested and suspended in 100 ⁇ l of cold HBSS buffer at cell concentrations of 1.0 ⁇ 10 6 cells/ml (CT-26 cells) or of 1.0 ⁇ 10 7 cells/ml (PAN02 cells) and subcutaneously (sc) injected into the mice using a 26 g syringe on day 0.
  • CT-26 cells 1.0 ⁇ 10 6 cells/ml
  • PAN02 cells 1.0 ⁇ 10 7 cells/ml
  • sc subcutaneously injected into the mice using a 26 g syringe on day 0.
  • the mice were randomized based on the tumor size followed by treatments with local radiation alone, gemcitabine alone (intravenous administration), ER-886046 alone (oral administration), or combinations of these treatments.
  • the animals that were assigned to the treatment groups in individual study had close mean tumor weights in all groups.
  • ER-886046 To evaluate whether addition of ER-886046 to anti-metabolite chemotherapy with radiation would improve anti-cancer activity in a preclinical animal model, multiple studies were carried out using murine pancreatic PAN02 tumors that grew subcutaneously in C57BL/6 mice, which received treatment with RT, and gemcitabine plus RT, both with or without ER-886046.
  • RT and gemcitabine were administered once on day 27 after tumor cell inoculation, while ER-886046 was given daily from day 27 until the end of the study.
  • FIG. 10 shows the average tumor sizes of the treatment groups from this study.
  • RT plus gemcitabine exhibited a weak but statistically significant tumor growth delay activity.
  • ER-886046 alone was more efficacious than RT plus gemcitabine.
  • a triple combination of ER-886046, RT and gemcitabine produced the best anti-tumor activity among the treatment groups, and the activity was significantly better than that of RT plus gemcitabine alone. Importantly, there was no significant difference in the anti-tumor activity between the triple combination group and ER-886046 plus RT group, indicating that most of the anti-tumor activity of the triple combination came from ER-886046 and RT.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US15/312,980 2014-05-23 2015-05-21 Combination therapies for the treatment of cancer Abandoned US20170182003A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/312,980 US20170182003A1 (en) 2014-05-23 2015-05-21 Combination therapies for the treatment of cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462002366P 2014-05-23 2014-05-23
US201562150004P 2015-04-20 2015-04-20
US15/312,980 US20170182003A1 (en) 2014-05-23 2015-05-21 Combination therapies for the treatment of cancer
PCT/US2015/031931 WO2015179615A1 (en) 2014-05-23 2015-05-21 Combination therapies for the treatment of cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/031931 A-371-Of-International WO2015179615A1 (en) 2014-05-23 2015-05-21 Combination therapies for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/528,510 Division US11707448B2 (en) 2014-05-23 2021-11-17 Combination therapies for the treatment of cancer

Publications (1)

Publication Number Publication Date
US20170182003A1 true US20170182003A1 (en) 2017-06-29

Family

ID=53277114

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/312,980 Abandoned US20170182003A1 (en) 2014-05-23 2015-05-21 Combination therapies for the treatment of cancer
US17/528,510 Active 2035-08-07 US11707448B2 (en) 2014-05-23 2021-11-17 Combination therapies for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/528,510 Active 2035-08-07 US11707448B2 (en) 2014-05-23 2021-11-17 Combination therapies for the treatment of cancer

Country Status (13)

Country Link
US (2) US20170182003A1 (ja)
EP (1) EP3134085A1 (ja)
JP (2) JP6787792B2 (ja)
KR (1) KR102535283B1 (ja)
CN (2) CN106572993B (ja)
AU (1) AU2015264102C1 (ja)
CA (1) CA2949961C (ja)
IL (1) IL249065A0 (ja)
MA (1) MA39906A (ja)
MX (1) MX2016015363A (ja)
RU (1) RU2708374C2 (ja)
SG (1) SG11201609770TA (ja)
WO (1) WO2015179615A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11382953B2 (en) * 2016-08-26 2022-07-12 Tetsuji Okuno Microvascular blood flow decreasing agent and use thereof
US11707448B2 (en) 2014-05-23 2023-07-25 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10316040B2 (en) 2015-10-16 2019-06-11 Eisai R&D Management Co., Ltd. EP4 antagonists
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
TWI795362B (zh) * 2016-07-07 2023-03-11 日商小野藥品工業股份有限公司 拮抗藥與免疫核查點阻礙藥而成之組合
EP3526323B1 (en) 2016-10-14 2023-03-29 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
DK3625222T3 (da) 2017-05-18 2021-10-25 Idorsia Pharmaceuticals Ltd Phenylderivater som pge2-receptormodulatorer
TW201900179A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物
HUE056382T2 (hu) 2017-05-18 2022-02-28 Idorsia Pharmaceuticals Ltd Pirimidin-származékok mint PGE2 receptor modulátorok
MX2019013639A (es) 2017-05-18 2020-01-21 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos.
CA3063788A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
CN108929281B (zh) * 2017-05-27 2021-12-24 华东师范大学 三氮唑类化合物及其合成方法和应用
US10617667B2 (en) * 2017-11-01 2020-04-14 Ono Pharmaceutical Co., Ltd. Method for treating brain tumors
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CA3084582A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN117643587A (zh) * 2018-02-05 2024-03-05 深圳市原力生命科学有限公司 用于治疗癌症的杂二环羧酸
CN111788204B (zh) 2018-02-26 2023-05-05 吉利德科学公司 作为hbv复制抑制剂的取代吡咯嗪化合物
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
KR20200140867A (ko) 2018-04-06 2020-12-16 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3'-사이클릭 다이뉴클레오티드
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
AU2019255196A1 (en) * 2018-04-16 2020-11-12 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
KR102650496B1 (ko) 2018-10-31 2024-03-26 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제제로서의 치환된 6-아자벤즈이미다졸 화합물
KR20210117280A (ko) 2019-01-22 2021-09-28 키테라 (쑤저우) 파마슈티컬스 컴퍼니 리미티드 Pge2/ep4 신호 전달을 억제하기 위한 화합물, 이의 제조 방법, 및 이의 의약적 용도
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
JP7350871B2 (ja) 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ２’３’－環状ジヌクレオチドおよびそのプロドラッグ
EP3935066A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN110386941A (zh) * 2019-08-15 2019-10-29 上海邦耀生物科技有限公司 Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
BR112022005687A2 (pt) 2019-09-30 2022-06-21 Gilead Sciences Inc Vacinas contra o hbv e métodos para tratar o hbv
US20230031465A1 (en) 2019-12-06 2023-02-02 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
IL296007A (en) * 2020-03-04 2022-10-01 Wuhan Humanwell Innovative Drug Res And Development Center Limited Company Synthesis of a new EP4 antibody and use for cancer and inflammation
KR20220156884A (ko) 2020-03-20 2022-11-28 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
CN114075140A (zh) * 2020-08-18 2022-02-22 武汉人福创新药物研发中心有限公司 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途
TW202227089A (zh) * 2020-11-30 2022-07-16 大陸商杭州阿諾生物醫藥科技有限公司 用於治療ｐｉｋ３ｃａ突變癌症的組合療法
WO2022161418A1 (zh) * 2021-01-28 2022-08-04 深圳晶泰科技有限公司 吡唑酰胺衍生物及其制备方法和应用
JP2024518558A (ja) 2021-05-13 2024-05-01 ギリアード サイエンシーズ， インコーポレイテッド ＴＬＲ８調節化合物と抗ＨＢＶ ｓｉＲＮＡ治療薬との組合せ
CA3222752A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
CA3222269A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
TW202328073A (zh) * 2021-09-03 2023-07-16 大陸商武漢人福創新藥物研發中心有限公司 Ｅｐ４拮抗劑化合物及其鹽、多晶型及其製備方法和用途
CN115364222A (zh) * 2021-09-09 2022-11-22 首都医科大学附属北京地坛医院 Ep4受体抑制剂治疗肝纤维化的应用
TW202339723A (zh) * 2021-12-30 2023-10-16 大陸商杭州阿諾生物醫藥科技有限公司 一種固體藥物組合物
WO2024027599A1 (zh) * 2022-08-04 2024-02-08 杭州阿诺生物医药科技有限公司 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012039972A1 (en) * 2010-09-21 2012-03-29 Eisai R&D Management Co., Ltd. Pharmaceutical composition
US20120088723A1 (en) * 2009-04-22 2012-04-12 Raqualia Pharma Inc. Selective ep4 receptor agonistic substance for treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
EP1691801A4 (en) * 2003-12-08 2009-12-09 Univ Arizona State SYNERGISTIC ANTICANCER COMPOSITIONS
SI2439273T1 (sl) 2005-05-09 2019-05-31 Ono Pharmaceutical Co., Ltd. Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki
CN101248089A (zh) 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
CA2660133C (en) * 2006-08-11 2015-10-27 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
CA2722811C (en) 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
SI2342226T1 (sl) 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
UA109108C2 (uk) 2008-12-09 2015-07-27 Дженентек, Інк. Антитіло до pd-l1 та його застосування для посилення функції t-клітин
AU2010303149B2 (en) 2009-09-30 2016-08-04 Board Of Regents, The University Of Texas System Combination immunotherapy for the treatment of cancer
US20150004175A1 (en) * 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
KR102535283B1 (ko) * 2014-05-23 2023-05-22 에자이 알앤드디 매니지먼트 가부시키가이샤 암의 치료를 위한 조합 요법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120088723A1 (en) * 2009-04-22 2012-04-12 Raqualia Pharma Inc. Selective ep4 receptor agonistic substance for treatment of cancer
WO2012039972A1 (en) * 2010-09-21 2012-03-29 Eisai R&D Management Co., Ltd. Pharmaceutical composition

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707448B2 (en) 2014-05-23 2023-07-25 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
US11382953B2 (en) * 2016-08-26 2022-07-12 Tetsuji Okuno Microvascular blood flow decreasing agent and use thereof

Also Published As

Publication number Publication date
CN110354266A (zh) 2019-10-22
CA2949961C (en) 2023-09-19
CN106572993B (zh) 2019-07-16
AU2015264102A1 (en) 2016-12-08
US20220071959A1 (en) 2022-03-10
JP2020128432A (ja) 2020-08-27
SG11201609770TA (en) 2016-12-29
IL249065A0 (en) 2017-01-31
CN106572993A (zh) 2017-04-19
EP3134085A1 (en) 2017-03-01
KR20170017933A (ko) 2017-02-15
CA2949961A1 (en) 2015-11-26
MA39906A (fr) 2017-03-01
JP6787792B2 (ja) 2020-11-18
RU2016150650A (ru) 2018-06-26
RU2708374C2 (ru) 2019-12-06
JP2017516775A (ja) 2017-06-22
KR102535283B1 (ko) 2023-05-22
RU2016150650A3 (ja) 2018-12-25
MX2016015363A (es) 2017-05-30
AU2015264102B2 (en) 2020-02-13
US11707448B2 (en) 2023-07-25
AU2015264102C1 (en) 2020-10-08
WO2015179615A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
US11707448B2 (en) Combination therapies for the treatment of cancer
Rios-Doria et al. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models
ES2835549T3 (es) Métodos de tratamiento de cánceres
KR102301175B1 (ko) 항종양 알칼로이드를 이용한 병용요법
JP2019031506A (ja) Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法
CN110869765A (zh) 组合疗法
JP6310144B2 (ja) がんを処置するための組み合わせ
JP2014132009A5 (ja)
JP2019510066A (ja) 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法
JP2012500180A5 (ja)
JP2014510729A (ja) 血液学的な悪性疾患のための併用療法
ES2768649T3 (es) Preparaciones para tratar un cáncer positivo para GD2
UA126313C2 (uk) Комбінована терапія
KR20200112904A (ko) 암을 치료하는 조성물 및 방법
CN114302745A (zh) 包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法
TW201306833A (zh) 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合
Pal et al. EXTH-80. PBI-200: in vivo efficacy of a novel, highly CNS-penetrant next generation TRK inhibitor
BR112016027512B1 (pt) Usos combinados de um antagonista de ep4 no tratamento de câncer e geração de uma resposta imune de memória contra um câncer
EP4085908A1 (en) Pharmaceutical combination for treating tumors and application thereof
Miller et al. A phase II study (Perseus) of two doses of EMD 525797 (DI17E6) in patients (pts) with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (mCRPC)

Legal Events

Date Code Title Description
AS Assignment

Owner name: EISAI R&D MANAGEMENT CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAO, XINGFENG;ALBU, DIANA;WOODALL-JAPPE, MARY;REEL/FRAME:040394/0098

Effective date: 20150518

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION